AstraZeneca exceeds sales and profits forecast amid coronavirus, outlook unchanged
Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.
Product sales, which exclude payments from tie-ups, rose 9 percent to $6.05 billion in the three months ended June 30 on a constant-currency basis, surpassing analysts’ consensus of $6.01 billion.
Core earnings stood at 96 cents per share versus analysts’ estimate of 93 cents. Total revenue rose 11 percent, AstraZeneca said.
Coronavirus: Abu Dhabi COVID-19 testing centers open during Eid al-AdhaMost COVID-19 health centers run by the Abu Dhabi Health Services Company (SEHA) will be open for testing during the Eid al-Adha holiday this weekend, ... Coronavirus
Coronavirus: Europe facing a second wave of COVID-19, says UK health ministerBritain’s Health Secretary Matt Hancock said on Thursday he was worried about a second wave of coronavirus infections in Europe and that the ... Coronavirus
Coronavirus: Brazil lifts ban on foreigners despite COVID-19 crisisBrazil reopened Wednesday to foreign visitors arriving by plane, hoping to revive its lockdown-devastated tourism industry despite the rapid spread of ... Coronavirus
Australia’s coronavirus outbreak continues to surge at alarming rateAustralia on Thursday reported a record number of new coronavirus infections and its deadliest day of the pandemic so far following a spike in cases ... Coronavirus